Skip to main content
S&P 5007,353.73-4.36%DOW51,523.06-3.44%NASDAQ24,315.00-5.52%BTC$76,146.00-5.78%ETH$2,238.88-7.96%GOLD$4,074.90-0.94%OIL$91.08+0.62%
Smart Investors Daily
SID Premium
EX

NASDAQ · EXEL

Exelixis, Inc.

Healthcare · Biotechnology

$68.71

Down-$4.04 (-5.55%)

Updated Nov 6, 2026, 6:16 AM

SID Score

7.9/10

Composite research score

Smart Money

58/100

Neutral

Market cap
11.1B
P/E ratio
16.39
Dividend yield
0.00%
52-week range
$37.58 – $73.44
Volume
4.61M
Avg. volume
2.76M

Price performance · EXEL

EXEL price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 5, 2026

EXEL closed at $68.71 after 21 trading sessions, up 16.42% for the selected period.

Last close
$68.71
Period change
+16.42%
Period low
$59.02
Period high
$72.75
Daily close
View OHLC price history
EXEL OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 5, 2026$73.03$73.69$68.46$68.714.61M
Nov 4, 2026$73.18$73.41$71.31$72.753.01M
Nov 3, 2026$70.11$73.44$70.11$72.313.85M
Nov 2, 2026$69.525$72.01$69.15$70.135.59M
Oct 30, 2026$68.28$72.10$67.05$69.395.07M
Oct 29, 2026$66.93$67.5199$65.06$66.202.84M
Oct 28, 2026$64.90$66.38$64.75$66.281.64M
Oct 27, 2026$64.70$65.48$64.385$65.351.43M
Oct 26, 2026$64.85$65.585$64.57$65.111.67M
Oct 23, 2026$65.15$65.20$63.91$64.532.07M
Oct 22, 2026$64.74$65.50$64.33$65.311.71M
Oct 21, 2026$64.12$64.7836$64.11$64.581.49M
Oct 20, 2026$63.01$64.42$62.845$64.392.14M
Oct 19, 2026$61.84$62.81$61.67$62.681.93M
Oct 16, 2026$62.98$63.39$61.74$62.232.64M
Oct 15, 2026$61.69$63.31$61.2801$62.832.77M
Oct 14, 2026$59.92$61.175$59.56$60.992.75M
Oct 13, 2026$60.00$60.00$58.59$59.512.62M
Oct 12, 2026$60.48$61.66$59.80$59.823.13M
Oct 9, 2026$59.00$60.83$59.00$59.862.67M
Oct 8, 2026$58.07$60.08$57.91$59.022.68M

Latest EXEL news

The latest Smart Investors Daily articles mentioning EXEL.

Stock researchCompany · Overview

EXEL research

Overview

Company profile and research snapshot.

Company profile

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$43.82
Implied upside
—
Analysts
—
EXEL recent ratings
DateFirmRatingTarget
Nov 2, 2026HC Wainwright & Co.Buy—
Oct 30, 2026Truist SecuritiesHold—
Oct 30, 2026RBC CapitalSector Perform—
Oct 30, 2026Morgan StanleyEqual-Weight—
Oct 30, 2026TD CowenBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 31, 2026

Earnings Beat Could Be A Game Changer For Exelixis Stock (EXEL)

Exelixis reported third quarter 2026 revenue of US$658.7 million and net income of US$218.1 million, with earnings per share above Wall Street expectations and full year revenue guidance maintained at US$2.5b to US$2.55b. The business leaned on its cabozantinib franchise while spotlighting zanzalintinib, which now has multiple pivotal trials running and an FDA action date set for its colorectal cancer filing in March 2027. The next step is to consider how Exelixis' investment narrative could...

Yahoo · Oct 31, 2026

Exelixis (EXEL) Beats Q3 Estimates, Is The Stock Fully Priced?

Exelixis (EXEL) is back in focus after its third quarter 2026 earnings, where revenue reached US$658.7 million and net income came in at US$218.1 million, both above last year’s levels. The earnings beat and steady 2026 guidance reset the tone around Exelixis, with the share price up 4.82% on the day and a 30 day share price return of 18.80%, contributing to a 59.22% year to date move. The 5 year total shareholder return of 258.42% shows how long term holders have already been rewarded even...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By